Valuation: AbbVie

Market Cap 455B 395B 368B 338B 638B 43,414B 648B 4,338B 1,702B 21,614B 1,708B 1,670B 72,474B P/E 2026 *
32.8x
P/E 2027 * 23.2x
Enterprise Value 511B 444B 414B 380B 717B 48,805B 728B 4,876B 1,914B 24,297B 1,920B 1,878B 81,472B EV / Sales 2026 *
7.59x
EV / Sales 2027 * 6.9x
Free-Float
95.71%
Yield 2026 *
2.74%
Yield 2027 * 2.88%
Manager TitleAgeSince
Chief Executive Officer 55 30/06/2024
Director of Finance/CFO 59 22/06/2022
Chief Tech/Sci/R&D Officer - 29/02/2024
Director TitleAgeSince
Director/Board Member 65 31/12/2012
Director/Board Member 74 31/12/2012
Director/Board Member 69 31/12/2012
Change 5-day change 1-year change 3-year change Capi.($)
-8.07%-3.48% - - 455B
-0.53%-3.12%+51.15%+150.58% 1,030B
+0.21%-1.13%+53.26%+46.92% 617B
+0.06%+1.17%+36.21%+31.25% 350B
-0.14%-0.83%+33.24%+40.28% 299B
-0.69%-0.44%+9.86%+14.23% 265B
-7.37%-4.31%-5.69%-41.99% 225B
-0.64%+3.68%+27.80%+62.95% 209B
-0.82%-0.50%+13.46%+69.41% 163B
+0.40%0.00%+5.04%-30.66% 142B
Average -1.46%+4.53%+24.93%+38.11% 366.65B
Weighted average by Cap. -1.30%+4.84%+35.81%+67.10%

Financials

2026 *2027 *
Net sales 67.36B 58.55B 54.5B 50.04B 94.49B 6,430B 95.96B 642B 252B 3,201B 253B 247B 10,734B 72.87B 63.35B 58.96B 54.13B 102B 6,956B 104B 695B 273B 3,463B 274B 268B 11,612B
Net income 13.89B 12.08B 11.24B 10.32B 19.49B 1,326B 19.79B 133B 52.01B 660B 52.18B 51.03B 2,214B 18.97B 16.49B 15.35B 14.1B 26.62B 1,811B 27.03B 181B 71.03B 902B 71.26B 69.7B 3,024B
Net Debt 56.47B 49.09B 45.69B 41.95B 79.21B 5,390B 80.44B 539B 211B 2,684B 212B 207B 8,998B 48.27B 41.96B 39.06B 35.86B 67.72B 4,608B 68.77B 460B 181B 2,294B 181B 177B 7,692B
Logo AbbVie
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
-
Trader
Investor
Global
Quality
-
ESG MSCI
AA